Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyntra Bio SEC filings document the former FibroGen public-company record, including the completed 2026 name change and common-stock ticker transition from FGEN to KYNB. Material-event reports cover operating results, clinical and regulatory disclosures for FG-3246, FG-3180 and roxadustat, capital-structure matters, Nasdaq continued-listing compliance notices, and the completed sale of FibroGen International (Hong Kong) Ltd. and related pro forma financial information.
Proxy materials address shareholder voting matters, board and governance practices, executive compensation, equity awards and related corporate-control disclosures. The filing record also includes formal amendments to organizational documents and other 8-K disclosures tied to the company’s biopharmaceutical development focus and corporate transformation.
KYNTRA BIO, INC. CEO and director Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, increasing his direct holdings to 27,203 shares. A separate line shows 40 shares of common stock held indirectly through his spouse.
KYNTRA BIO, INC. CEO Thane Wettig reported an open-market purchase of common stock. He bought 2,800 shares on May 14, 2026 at a price of $7.09 per share, bringing his direct holdings to 27,203 shares. He also reports indirect ownership of 40 shares held by his spouse.
KYNTRA BIO, INC. filing shows Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 400,000 shares of common stock, representing 9.88% of the class.
The filing states Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares; Mr. Boyd is the managing member of Armistice Capital. Signatures are dated May 15, 2026.
Kyntra Bio, Inc. reported first-quarter 2026 revenue of $3.7 million, up from $2.7 million a year earlier, driven mainly by $3.5 million of drug product sales of roxadustat API and bulk product to Astellas. Operating costs and expenses were $17.6 million, roughly flat year over year.
The company posted a loss from continuing operations of $15.1 million, or $3.74 per share, compared with a loss of $16.8 million, or $4.15 per share, in 2025. Net loss was $15.2 million versus net income of $4.6 million last year, when results included $21.4 million of income from discontinued China operations. Cash, cash equivalents, short- and long-term investments, and accounts receivable totaled about $100.3 million, and management believes this will fund operations for at least 12 months. Kyntra continues to develop FG-3246 for metastatic castration-resistant prostate cancer and advance roxadustat into a planned Phase 3 trial for anemia in lower-risk MDS.
Kyntra Bio reported first quarter 2026 results, showing total revenue from continuing operations of $3.7 million, up from $2.7 million a year earlier, driven mainly by higher drug product revenue. Net loss from continuing operations narrowed to $15.1 million, or $3.74 per share, compared with a $16.8 million loss, or $4.15 per share, in 2025.
The company ended March 31, 2026 with $100.3 million in cash, cash equivalents, investments, and accounts receivable and expects this to fund its operating plans into 2028. Kyntra highlighted steady progress in its pipeline, including an actively enrolling Phase 2 trial of FG-3246 in metastatic castration-resistant prostate cancer with an interim analysis planned for the fourth quarter of 2026, and finalization of a pivotal Phase 3 roxadustat protocol in lower-risk myelodysplastic syndromes ahead of a targeted trial start in the second half of 2026.
Kyntra Bio, Inc. will hold its 2026 Annual Meeting of Stockholders as a virtual-only live audio webcast on June 12, 2026 at 8:00 a.m. Pacific Time. Stockholders as of the April 16, 2026 record date, when 4,048,112 common shares were outstanding, may vote.
Stockholders are asked to elect Class III director Michael Kauffman, M.D., Ph.D., approve on an advisory basis the compensation of named executive officers, and ratify PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026.
The five-member Board includes four independent directors and is led by independent Chair James A. Schoeneck. Committees oversee audit, compensation, and governance, including enterprise risk management, cybersecurity, and ESG programs. Non-employee directors receive cash retainers and stock options under the 2024 Equity Incentive Plan.
Kyntra Bio, Inc. reported receiving a Nasdaq notice on April 2, 2026 that it no longer meets the Nasdaq Global Select Market continued listing requirement of $50 million in total assets and total revenue under Listing Rule 5450(b)(3)(A).
The shortfall arises because revenue of FibroGen International is now presented as held for sale in discontinued operations for 2024 and 2025, and the company also does not meet the alternative shareholders’ equity or market value standards. Kyntra Bio has 45 days, until May 18, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to a 180‑day extension to September 29, 2026 if the plan is accepted.
Kyntra Bio, Inc., formerly FibroGen, is a biopharmaceutical company focused on cancer and anemia, highlighted by a 2025 rebranding and new Nasdaq symbol KYNB. The company’s lead oncology asset is FG-3246, a CD46-targeting antibody-drug conjugate for metastatic castration-resistant prostate cancer, now in a Phase 2 monotherapy dose-optimization trial with an FG-3180 PET imaging companion.
Kyntra continues to develop roxadustat, already approved for chronic kidney disease anemia in multiple territories through partners, while preparing a Phase 3 trial in lower-risk myelodysplastic syndromes after FDA alignment and Orphan Drug Designation in 2025. In August 2025, it sold its China roxadustat operations to AstraZeneca for $220.4 million, retaining rights in the U.S., Canada, Mexico and other markets. Revenue is primarily driven by collaborations with Astellas and AstraZeneca, supported by a revenue-interest financing with NovaQuest and an exclusive option to acquire Fortis Therapeutics, which licensed FG-3246.
Kyntra Bio reported fourth quarter and full-year 2025 results and highlighted progress in its oncology and rare disease pipeline. The company is running a Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer, with an interim analysis planned in the second half of 2026, and reported encouraging investigator-sponsored combination data with enzalutamide presented at ASCO meetings.
Kyntra submitted a pivotal Phase 3 protocol for roxadustat in anemia due to lower-risk myelodysplastic syndromes to the FDA and is evaluating whether to advance this program alone or with a partner. Total revenue from continuing operations fell to $6.4 million in 2025 from $29.6 million in 2024, but the net loss from continuing operations narrowed to $58.2 million from $153.1 million, reflecting a restructuring and portfolio shift. The company ended 2025 with $109.4 million in cash, cash equivalents, investments, and accounts receivable and currently expects this to fund operating plans into 2028.
KYNTRA BIO, INC. CEO and director Thane Wettig reported a routine tax-related share disposition. On March 6, 2026, 277 shares of common stock were withheld by the issuer at $6.84 per share to satisfy taxes due upon the vesting of restricted stock units. After this withholding, Wettig held 24,403 common shares directly, and an additional 40 shares were held indirectly by his spouse.